oasis 4 semaglutide 25 mg Novo Nordisk's Wegovy® pill (oral mg, once daily) has just been approved by the US FDA as the first oral GLP‑1 receptor agonist for long‑term weight management and CV risk 🚨 Oral Semaglutide 25 mg

That opened Pandora's box

This means that even compliant ingredients can trigger enforcement if marketing language suggests unapproved uses or benefits and the way suppliers are selling peptides

Studies tracking semaglutide use for 23+ years demonstrate sustained efficacy with manageable side effects that typically diminish after 48 weeks of treatment

GLP-1RAs have also shown anti-thrombotic effects

J Med Chem 1994

FDA is now increasing foreign API manufacturer oversight via inspections, use of remote document requests and Import Alerts, placing foreign manufacturers on the so-called Red List for failure to provide or provide access to documents or records under section 704(a) of the FD&C Act